RESUMEN
Benzoyl peroxide (BPO) has been widely used to treat acne vulgaris. Skin flaking, erythema and skin irritation have been observed as side effects of BPO in the treatment of this disorder. In a clinical study, cherry bark-containing jumihaidokuto significantly reduced the erythema induced by BPO application. However, its mechanism of action has not been clarified. In the present study, an application of 10% BPO caused erythema and an increase in interleukin (IL)-1α in the skin of hairless mice, and these changes were significantly suppressed by cherry bark-containing jumihaidokuto at 600 mg/kg. In addition, using a three-dimensional cultured human epidermis model (LabCyte EPI-MODEL), cherry bark-containing jumihaidokuto extract at 250 or 500 µg/mL significantly suppressed IL-1α mRNA expression induced by the application of 0.2 mM BPO. Therefore, cherry bark-containing jumihaidokuto may have suppressed BPO-induced erythema by inhibiting the increase in the IL-1α level in the skin.
Asunto(s)
Peróxido de Benzoílo/efectos adversos , Eritema/inducido químicamente , Eritema/tratamiento farmacológico , Fitoterapia , Extractos Vegetales/uso terapéutico , Acné Vulgar/tratamiento farmacológico , Animales , Peróxido de Benzoílo/uso terapéutico , Células Cultivadas , Quimioterapia Combinada , Epidermis/metabolismo , Eritema/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Interleucina-1alfa/genética , Interleucina-1alfa/metabolismo , Masculino , Ratones Pelados , Corteza de la Planta/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
Effective therapies for adult female acne (AFA) are limited. Oral spironolactone (SPL), 100-200 mg/day, is currently used off-label to treat AFA. However, high-dose SPL results in clinically significant side-effects which prevent widespread use in clinical practice. The efficacy of low-dose spironolactone in AFA is unknown. We examined the efficacy and tolerability of low-dose (25-50 mg/day) oral SPL in Thai women with moderate AFA. A randomized, double-blind, placebo-controlled trial was conducted for 12 weeks. Moderate AFA patients aged between 25 and 45 years received a combination of daily topical benzoyl peroxide (BP) 2.5% plus either SPL 25 mg (SPL25 group), SPL 50 mg (SPL50 group) or placebo. We performed total acne counts and Adult Female Acne Scoring Tool (AFAST) grading at 4-week intervals. The success rate, defined as the proportion of participants achieving a "clear/almost clear" AFAST grade by the end of week 12, was considered as the main outcome. Treatment-related adverse events (TRAE) were recorded. We enrolled 63 participants in the study. The total acne counts decreased significantly in all three groups (P < 0.05) as compared with baseline. Participants in the SPL50 group had a significantly higher success rate than those in the placebo group (P < 0.05). Serum potassium and creatinine levels showed no significant changes with treatment or between groups. A small number of participants in SPL25 and SPL50 reported mild and temporary TRAE, such as menstrual irregularities, breast tenderness and dizziness. The combination of SPL 50 mg/day and topical BP proved effective in improving moderate AFA in Thai women, with an acceptable side-effect profile. We propose this regimen as an option for treating moderate AFA.
Asunto(s)
Acné Vulgar , Fármacos Dermatológicos , Acné Vulgar/tratamiento farmacológico , Administración Cutánea , Adulto , Peróxido de Benzoílo/efectos adversos , Fármacos Dermatológicos/uso terapéutico , Método Doble Ciego , Combinación de Medicamentos , Femenino , Geles/uso terapéutico , Humanos , Persona de Mediana Edad , Espironolactona/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND: Although there is a standard guideline for the treatment of acne, it is still a common skin disease, and suboptimal medication adherence is a major reason for treatment failure. Herbal extracts are an interesting alternative medicine because they consist of a variety of active ingredients. Moreover, herbal extracts may have improved therapeutic efficacy because of the combination of various herbs. OBJECTIVES: To evaluate the effectiveness of herbal extracts for the treatment of mild to moderate acne vulgaris. METHODS: A total of 77 patients were randomized to receive either an herbal extract or 2.5% benzoyl peroxide, which were applied for a period of 12 weeks. Acne lesion counts, adherence, porphyrin counts, the Dermatology Life Quality Index, satisfaction and side effects were assessed. RESULT: At the 12-week point, the acne lesion counts decreased, with statistically significant differences from the baseline values in both groups and for all types of acne (P-value < 0.001). The adherence rate was significantly higher in the patients using the herbal extract than in the patients using 2.5% benzoyl peroxide (P-value = 0.002). There was no statistically significant difference in terms of porphyrin counts, spot scores, the Dermatology Life Quality Index or satisfaction with efficacy between the groups; however, satisfaction with drug administration was significantly higher in the patients using the herbal extract (P-value = 0.001). CONCLUSION: Herbal extracts could be beneficial for anti-acne pharmaceutical preparations and may be used as an alternative medicine for patients with mild to moderate acne vulgaris who do not adhere to benzoyl peroxide treatment.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Peróxido de Benzoílo/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Cumplimiento de la Medicación/estadística & datos numéricos , Extractos Vegetales/administración & dosificación , Acné Vulgar/diagnóstico , Acné Vulgar/psicología , Peróxido de Benzoílo/efectos adversos , Fármacos Dermatológicos/efectos adversos , Femenino , Humanos , Masculino , Satisfacción del Paciente , Extractos Vegetales/efectos adversos , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenRESUMEN
Combination therapy using medications with complementary mechanisms of action is the standard of care in treating acne. We report results of a clinical trial evaluating the use of a fixed-dose tretinoin 0.025%/clindamycin phosphate 1.2% (T/CP) gel in combination with a benzoyl peroxide 6% foaming cloth compared with T/CP alone for facial acne. At week 12, the combination therapy group showed a trend toward greater efficacy compared with T/CP alone. There was a high success rate observed in the study, which may be attributable to the large percentage of adult female acne patients enrolled. Cutaneous adverse events were not statistically different in using combination therapy compared with T/CP alone.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Peróxido de Benzoílo/uso terapéutico , Clindamicina/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Tretinoina/uso terapéutico , Acné Vulgar/patología , Administración Cutánea , Adolescente , Adulto , Peróxido de Benzoílo/administración & dosificación , Peróxido de Benzoílo/efectos adversos , Clindamicina/administración & dosificación , Clindamicina/efectos adversos , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Combinación de Medicamentos , Quimioterapia Combinada , Cara , Femenino , Geles , Humanos , Masculino , Persona de Mediana Edad , Método Simple Ciego , Tretinoina/administración & dosificación , Tretinoina/efectos adversos , Adulto JovenRESUMEN
This article reviews various studies supporting the use of a fixed-combination monotherapy hydrating gel containing clindamycin 1% and benzoyl peroxide 5% (C/BPO), which is the only available formulation with a hydrating gel vehicle containing a humectant and an occlusive. The C/BPO hydrating gel provides a flexible and complementary efficacy and/or tolerability profile when used alone or with topical retinoids, which results in rapid response in inflammatory and noninflammatory acne. It also mitigates the irritation associated with disease flare or topical retinoid use, and reduces the postinflammatory hyperpigmentation (PIH) seen in women and in patients with skin of color with acne. These benefits are important because they have the potential to improve patient adherence to therapy and clinical outcomes.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Peróxido de Benzoílo/uso terapéutico , Clindamicina/uso terapéutico , Acné Vulgar/patología , Administración Cutánea , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Peróxido de Benzoílo/administración & dosificación , Peróxido de Benzoílo/efectos adversos , Clindamicina/administración & dosificación , Clindamicina/efectos adversos , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Fármacos Dermatológicos/uso terapéutico , Combinación de Medicamentos , Sinergismo Farmacológico , Excipientes/química , Geles , HumanosRESUMEN
FUNDAMENTOS: Muitos pacientes relatam melhora da acne com a exposição à luz solar, e vários estudos demonstram que a luz azul é efetiva no tratamento da acne. OBJETIVOS: Verificar a segurança e a eficácia da luz azul (espectro eletromagnético de 407 a 420 nm) no tratamento da acne inflamatória graus II e III, comparada à terapêutica tópica com peróxido de benzoíla a 5 por cento. MÉTODOS: O estudo avaliou 60 pacientes em cinco visitas: uma de seleção, uma com 7, 14 e 28 dias de tratamento e uma última de seguimento, 14 dias após o término do tratamento. Trinta foram randomizados para luz azul (oito sessões, duas vezes por semana), e outros 30, para peróxido de benzoíla a 5 por cento, duas vezes ao dia, diariamente. A avaliação foi por meio da contagem das lesões e fotografias. RESULTADOS: A redução no número médio de lesões foi semelhante com os dois tratamentos, independente do tipo de lesão (p 0,05), porém o tratamento com a luz azul apresentou menos efeitos colaterais. CONCLUSÕES: A luz azul foi um tratamento tão eficaz quanto o peróxido de benzoíla a 5 por cento para o tratamento da acne graus II e III, mas com menos efeitos adversos.
BACKGROUND: Many acne patients improve after exposure to sunlight and there are many reports about the efficacy of blue light phototherapy on acne lesions. OBJECTIVES - The purpose of this study was to evaluate efficacy and safety of blue light treatment versus topical benzoyl peroxide 5 percent formulation in patients with acne grades II and III. METHODS - Sixty volunteers with facial acne were included and evaluated in 5 visits: the first one for screening, another 3 held on days 7, 14 and 28 of treatment, and the last one after 14 days of the end of treatment. Thirty of them were irradiated with Blue Light (8 times, twice a week) and the other thirty were treated with topical Benzoyl Peroxide 5 percent formulation, auto-applied twice a day, every day. We assessed the severity of acne by counting the lesions and analyzing the photographs. RESULTS - The improvement achieved by the blue light was the same as the one with benzoyl peroxide, regardless of the type of lesion (p 0.05). Otherwise, the side effects were less frequent in the group treated with blue light. CONCLUSIONS - Blue light irradiation was as effective as Benzoyl Peroxide in acne treatment grades II and III but there were fewer side effects.
Asunto(s)
Adolescente , Femenino , Humanos , Masculino , Acné Vulgar/terapia , Peróxido de Benzoílo/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Fototerapia , Administración Tópica , Peróxido de Benzoílo/efectos adversos , Fármacos Dermatológicos/efectos adversos , Estudios Prospectivos , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: Many acne patients improve after exposure to sunlight and there are many reports about the efficacy of blue light phototherapy on acne lesions. OBJECTIVES: The purpose of this study was to evaluate efficacy and safety of blue light treatment versus topical benzoyl peroxide 5% formulation in patients with acne grades II and III. METHODS: Sixty volunteers with facial acne were included and evaluated in 5 visits: the first one for screening, another 3 held on days 7, 14 and 28 of treatment, and the last one after 14 days of the end of treatment. Thirty of them were irradiated with Blue Light (8 times, twice a week) and the other thirty were treated with topical Benzoyl Peroxide 5% formulation, auto-applied twice a day, every day. We assessed the severity of acne by counting the lesions and analyzing the photographs. RESULTS: The improvement achieved by the blue light was the same as the one with benzoyl peroxide, regardless of the type of lesion (p 0.05). Otherwise, the side effects were less frequent in the group treated with blue light. CONCLUSIONS: Blue light irradiation was as effective as benzoyl peroxide in acne treatment grades II and III but there were fewer side effects.
Asunto(s)
Acné Vulgar/terapia , Peróxido de Benzoílo/administración & dosificación , Fármacos Dermatológicos/administración & dosificación , Fototerapia , Administración Tópica , Adolescente , Peróxido de Benzoílo/efectos adversos , Fármacos Dermatológicos/efectos adversos , Femenino , Humanos , Masculino , Estudios Prospectivos , Índice de Severidad de la EnfermedadRESUMEN
In this study we have evaluated the use of blue light (peak at 415 nm) and a mixed blue and red light (peaks at 415 and 660 nm) in the treatment of acne vulgaris. One hundred and seven patients with mild to moderate acne vulgaris were randomized into four treatment groups: blue light, mixed blue and red light, cool white light and 5% benzoyl peroxide cream. Subjects in the phototherapy groups used portable light sources and irradiation was carried out daily for 15 min. Comparative assessment between the three light sources was made in an observer-blinded fashion, but this could not be achieved for the use of benzoyl peroxide. Assessments were performed every 4 weeks. After 12 weeks of active treatment a mean improvement of 76% (95% confidence interval 66-87) in inflammatory lesions was achieved by the combined blue-red light phototherapy; this was significantly superior to that achieved by blue light (at weeks 4 and 8 but not week 12), benzoyl peroxide (at weeks 8 and 12) or white light (at each assessment). The final mean improvement in comedones by using blue-red light was 58% (95% confidence interval 45-71), again better than that achieved by the other active treatments used, although the differences did not reach significant levels. We have found that phototherapy with mixed blue-red light, probably by combining antibacterial and anti-inflammatory action, is an effective means of treating acne vulgaris of mild to moderate severity, with no significant short-term adverse effects.
Asunto(s)
Acné Vulgar/terapia , Fototerapia/métodos , Adolescente , Adulto , Peróxido de Benzoílo/efectos adversos , Peróxido de Benzoílo/uso terapéutico , Fármacos Dermatológicos/efectos adversos , Fármacos Dermatológicos/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fototerapia/efectos adversos , Método Simple Ciego , Resultado del TratamientoRESUMEN
A retrospective questionnaire was conducted as to the risk factors for facial skin cancer with emphasis on acne and past treatments for acne, in particular use of benzoyl peroxide preparations. The response rate was 90.9% for 964 cases and 79.9% for 3856 controls. There was no association between acne and the use of any acne medication for the risk of facial skin cancer. Cases of skin cancer were significantly more likely to have used phototherapy or sunbeds than the controls (P = 0.024), and more likely to have had radiotherapy prior to diagnosis (P = 0.001). The major risk factors as determined by generalized linear interactive modelling were family history of skin cancer (odds ratio 2.68; 95% confidence interval 2.15, 3.34), light skin (1.54; 1.25, 1.89), sunburning easily (1.43; 1.16, 1.76) and Irish, Scottish, Scandinavian or German mothers (1.33; 1.11, 1.59).
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Peróxido de Benzoílo/efectos adversos , Neoplasias de Cabeza y Cuello/inducido químicamente , Neoplasias Cutáneas/inducido químicamente , Adulto , Femenino , Humanos , Masculino , Oportunidad Relativa , Fototerapia/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/genética , Quemadura Solar/complicacionesRESUMEN
To investigate the effects of two levels of dietary corn oil on tumorigenesis, semipurified diets containing 5% or 10% corn oil were fed during the promotion stage of a mouse skin carcinogenesis model. Sencar mice were initiated with 10 nmol dimethylbenz[a]anthracene (DMBA) and promoted with either 1 microgram 12-O-tetradecanoylphorbol-13-acetate (TPA) or 40 mg benzoyl peroxide twice weekly for 24 or 52 weeks, respectively. No significant differences in kilocalories of food consumed or body weights were observed between the diet groups during the study. Fatty acid profiles of the epidermal phospholipids reflected dietary fat intake. For example, high levels of linoleate and low levels of arachidonate were found in the phosphatidylcholine fraction from mice fed the 10% corn oil diet compared with 5% corn oil. When the diets were fed during TPA promotion, the papilloma incidence after 11 weeks of treatment for the 5% corn oil group was 77% and 37% for the 10% corn oil group. By 15 weeks of TPA treatment, papilloma incidence between the diet groups was similar, and later, carcinoma incidence and yield were not different between the two groups. For the animals treated with benzoyl peroxide, there was only a slight but not significant difference in papilloma and carcinoma appearance. In parallel studies, ornithine decarboxylase activity, vascular permeability, hyperplasia, and prostaglandin E2 (PGE2) levels were elevated in the epidermis after promoter treatment, but only hyperplasia and PGE2 synthesis tended to reflect the dietary effects on tumor appearance. These data suggest that the quantity of dietary corn oil at the two levels tested, 5% and 10%, altered epidermal phospholipid fatty acid composition and PGE2 levels and had modest effects on the modulation of tumorigenesis in this skin model.
Asunto(s)
9,10-Dimetil-1,2-benzantraceno/efectos adversos , Cocarcinogénesis , Aceite de Maíz/farmacología , Grasas de la Dieta/farmacología , Neoplasias Cutáneas/inducido químicamente , Animales , Peróxido de Benzoílo/efectos adversos , Permeabilidad Capilar/efectos de los fármacos , Aceite de Maíz/administración & dosificación , Grasas de la Dieta/administración & dosificación , Dinoprostona/análisis , Ácidos Grasos/análisis , Femenino , Hiperplasia , Ratones , Ornitina Descarboxilasa/análisis , Fosfolípidos/análisis , Piel/irrigación sanguínea , Piel/química , Piel/efectos de los fármacos , Piel/enzimología , Piel/patología , Neoplasias Cutáneas/irrigación sanguínea , Neoplasias Cutáneas/química , Neoplasias Cutáneas/enzimología , Neoplasias Cutáneas/patología , Acetato de Tetradecanoilforbol/efectos adversosRESUMEN
Tea-tree oil (an essential oil of the Australian native tree Melaleuca alternifolia) has long been regarded as a useful topical antiseptic agent in Australia and has been shown to have a variety of antimicrobial activities; however, only anecdotal evidence exists for its efficacy in the treatment of various skin conditions. We have performed a single-blind, randomised clinical trial on 124 patients to evaluate the efficacy and skin tolerance of 5% tea-tree oil gel in the treatment of mild to moderate acne when compared with 5% benzoyl peroxide lotion. The results of this study showed that both 5% tea-tree oil and 5% benzoyl peroxide had a significant effect in ameliorating the patients' acne by reducing the number of inflamed and non-inflamed lesions (open and closed comedones), although the onset of action in the case of tea-tree oil was slower. Encouragingly, fewer side effects were experienced by patients treated with tea-tree oil.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Peróxido de Benzoílo/uso terapéutico , Aceites Volátiles/uso terapéutico , Aceites de Plantas/uso terapéutico , Árboles , Acné Vulgar/patología , Adolescente , Adulto , Peróxido de Benzoílo/administración & dosificación , Peróxido de Benzoílo/efectos adversos , Niño , Femenino , Geles , Humanos , Masculino , Aceites Volátiles/administración & dosificación , Aceites Volátiles/efectos adversos , Aceites de Plantas/administración & dosificación , Aceites de Plantas/efectos adversos , Estudios Prospectivos , Método Simple Ciego , Piel/patología , Factores de TiempoRESUMEN
Benzoyl peroxide (BP) is shown to be a weak allergen. Of 25 guinea pigs, only 5 were sensitized in the TINA test. Before treatment, only 2 of 172 acne patients gave a positive patch test with 1% BP, but not with 0.1% BP. The following results suggest that BP is a strong irritant. The irritant potential ID50 in rabbits was 2.52%, and the IT50 was 2.31 days with 5% BP, 4.34 days with 1% and 8.35 days with 0.1% BP. 29% of acne patients and non-exposed controls had a positive patch test with 5% BP. However, only 11 of 155 acne patients had clinical signs of intolerance, which settled despite continued use in 10 cases. The possible reasons for this dichotomy are explored. Neither the irritant nor allergenic properties of BP impaired its clinical use.